As an epidemiologist, I develop large databases of gastrointestinal (GI) motility tests and procedures with millions of data points to infer hypotheses that will be used in drug and device development in gastroenterology in conjunction with work done by my colleagues, Mark Pimentel, MD, and Ruchi Mathur, MD.
GI motility disorder and inflammatory bowel disease (IBD) specialists, the two fastest-growing fields of luminal gastroenterology, are falling short of close collaborations because of the overly subspecialized nature of these disciplines. My formal postgraduate training and research experience in both fields gives me a unique set of skills for nurturing a strong and constructive collaboration between the two disciplines.
This is proving to be extremely important in providing care for IBD patients, who commonly suffer from concomitant GI motility disorders such as irritable bowel syndrome, small intestinal bacterial overgrowth, fecal incontinence, dyssynergic defecation, dyspepsia, gastroparesis and gastroesophageal reflux disease. Moreover, I am involved in the development of technologies that offer alternatives to antibiotics and immunosuppressants.